Skip to main content
. 2019 Nov 12;93(1115):20190829. doi: 10.1259/bjr.20190829

Table 2.

Comparisons of cohorts in recent ophthalmological studies

End points Cohorts
Atomic bomb survivors Mayak workers Radiologic technologists
Countries Japan Russia US
Rounded number of eligible study participants 900–10,000 21,000 70,000
Male:female one to 2 three to 1 one to 3
Follow-up ≤60 yearsa ≤60 yearsb ≤92 yearsc
Mean follow-up ≤60 yearsa >30 yearsb >10 yearsc
Medical information Biennial health exams Annual health exams Periodic questionnaire surveysd
Exposure scenarios Acute Chronic Protracted
Dose evaluated Eye absorbed dosee Hp(10)f Lens absorbed doseg
Mean dose ~0.5 Gye ~0.5 Svf ~0.06 Gyg
Radiation cataracts in aggregate Significantly increased Significantly increased Significantly increased
Radiation posterior subcapsular cataracts Significantly increased Significantly increased N.A.
Radiation cortical cataracts Significantly increased Significantly increased N.A.
Radiation nuclear cataracts N.S. Significantly increased N.A.
Radiation cataract surgery Significantly increased N.S. N.S.
Radiation glaucoma in aggregate Significantly decreased N.A. N.S.
Radiation primary glaucoma N.A. N.S. N.A.
Radiation primary open-angle glaucoma N.A. N.S. N.A.
Radiation primary open-angle normal-tention glaucoma Significantly increased N.A. N.A.
Radiation primary open-angle high-tention glaucoma N.S. N.A. N.A.
Radiation primary angle-closure glaucoma N.S. N.A. N.A.
Radiation diabetic retinopathy Significantly increased N.A. N.A.
Radiation macular degeneration N.S. N.A. N.S.

NA, not available; NS, not significant.

a

Those exposed in 1945 were followed up through 2005.

b

Those first employed in 1948–1982 were followed up through 2008.

c

Those certified as radiologic technologists for ≥2 years in 1928–1982 were followed up through 2014.

d

Self-reporting but by medically literate individuals.

e

According to the Dosimetry System 2002 (DS02).24

f

According to the Mayak Worker Dosimetry System 2008 (MWDS–2008).25

g

According to the updated and improved dosimetry.26